Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1987 1
1990 1
2009 1
2010 1
2012 2
2013 2
2014 4
2015 9
2016 6
2017 5
2018 3
2019 8
2020 14
2021 8
2022 5
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Zhou C, et al. Among authors: kitazono s. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870976 Clinical Trial.
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
Shimizu T, Sands J, Yoh K, Spira A, Garon EB, Kitazono S, Johnson ML, Meric-Bernstam F, Tolcher AW, Yamamoto N, Greenberg J, Kawasaki Y, Zebger-Gong H, Kobayashi F, Phillips P, Lisberg AE, Heist RS. Shimizu T, et al. Among authors: kitazono s. J Clin Oncol. 2023 Oct 10;41(29):4678-4687. doi: 10.1200/JCO.23.00059. Epub 2023 Jun 16. J Clin Oncol. 2023. PMID: 37327461 Free PMC article. Clinical Trial.
Minimal Change Disease Associated With Durvalumab.
Toda MG, Fujii K, Kato A, Yoshifuji A, Komatsu M, Amino Y, Kitazono S, Hashiguchi A, Ryuzaki M. Toda MG, et al. Among authors: kitazono s. Kidney Int Rep. 2021 Sep 1;6(10):2733-2734. doi: 10.1016/j.ekir.2021.08.021. eCollection 2021 Oct. Kidney Int Rep. 2021. PMID: 34622115 Free PMC article. No abstract available.
Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight.
Fujiwara Y, Makihara R, Hase T, Hashimoto N, Naito T, Tsubata Y, Okuno T, Takahashi T, Kobayashi H, Shinno Y, Zenke Y, Ikeda T, Hosomi Y, Watanabe K, Kitazono S, Sakiyama N, Makino Y, Yamamoto N. Fujiwara Y, et al. Among authors: kitazono s. Cancer Sci. 2023 May;114(5):2087-2097. doi: 10.1111/cas.15736. Epub 2023 Feb 14. Cancer Sci. 2023. PMID: 36704833 Free PMC article.
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).
Uematsu S, Kitazono S, Tanaka H, Saito R, Kawashima Y, Ohyanagi F, Tozuka T, Ryosuke T, Sakatani T, Horiike A, Yoshizawa T, Saiki M, Tambo Y, Koyama J, Kanazu M, Kudo K, Tsuchiya-Kawano Y, Yanagitani N, Nishio M. Uematsu S, et al. Among authors: kitazono s. Thorac Cancer. 2023 Jan;14(2):168-176. doi: 10.1111/1759-7714.14729. Epub 2022 Nov 21. Thorac Cancer. 2023. PMID: 36408699 Free PMC article.
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients.
Tozuka T, Yanagitani N, Yoshida H, Manabe R, Ogusu S, Tsugitomi R, Sakamoto H, Amino Y, Ariyasu R, Uchibori K, Kitazono S, Seike M, Gemma A, Nishio M. Tozuka T, et al. Among authors: kitazono s. Invest New Drugs. 2023 Jun;41(3):411-420. doi: 10.1007/s10637-023-01358-3. Epub 2023 Apr 14. Invest New Drugs. 2023. PMID: 37058183
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Imai H, Kijima T, Azuma K, Kishi K, Saito H, Yamaguchi T, Tanizaki J, Yoneshima Y, Fujita K, Watanabe S, Kitazono S, Fukuhara T, Hataji O, Toi Y, Mizutani H, Hamakawa Y, Maemondo M, Ohsugi T, Suzuki K, Horinouchi H, Ohe Y. Imai H, et al. Among authors: kitazono s. Jpn J Clin Oncol. 2024 Apr 6;54(4):452-462. doi: 10.1093/jjco/hyad195. Jpn J Clin Oncol. 2024. PMID: 38271158 Free PMC article.
Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy.
Ariyasu R, Horiike A, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Nishio M. Ariyasu R, et al. Among authors: kitazono s. Anticancer Res. 2017 Aug;37(8):4229-4232. doi: 10.21873/anticanres.11814. Anticancer Res. 2017. PMID: 28739711
Clinical characteristics of patients with KRAS mutation detected by liquid biopsy.
Amino Y, Low SK, Ninomiya H, Kiritani A, Miyadera K, Kakuto S, Akita T, Tsugitomi R, Ariyasu R, Uchibori K, Kitazono S, Yanagitani N, Nishio M. Amino Y, et al. Among authors: kitazono s. Thorac Cancer. 2023 Nov;14(33):3317-3322. doi: 10.1111/1759-7714.15123. Epub 2023 Sep 26. Thorac Cancer. 2023. PMID: 37751775 Free PMC article.
72 results